Platinum complex cytotoxicity tested by the electrical resistance breakdown assay

Cellular Physiology and Biochemistry

Volumn 14, Issue 4-6, 2004, Pages 425-430

  Ludwig, Thomas ^a   Fakih, Sarah ^a   Krebs, Bernt ^a   Oberleithner, Hans ^a  

^a UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

Cytostatic activity; Platinum complexes; Renal epithelia; Toxicity; Transepithelial electrical resistance

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; CARBOPLATIN; CISPLATIN; CISPLATIN DERIVATIVE; PLATINUM COMPLEX;

AMELANOTIC MELANOMA; ANALYTIC METHOD; ARTICLE; CELL INVASION; CELL METABOLISM; COCULTURE; CONTROLLED STUDY; CYTOSTASIS; ELECTRIC RESISTANCE; ENZYME ACTIVITY; HUMAN; HUMAN CELL; MONOLAYER CULTURE; PRIORITY JOURNAL; TOXICITY TESTING;

EID: 4444366022     PISSN: 10158987     EISSN: None     Source Type: Journal    
DOI: 10.1159/000080358     Document Type: Article

References (28)

1. Mosmann T: Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983:65:55-63.
2. Hansen MB, Nielsen SE, Berg K: Reexamination and further development of a precise and rapid dye method for measuring cell growth/cell kill. J Immunol Methods 1989:119:203-210.
3. Scudiero DA, Shoemaker RH, Paull KD, Monks A, Tierney S, Nofziger TH, Currens MJ, Seniff D, Boyd MR: Evaluation of a soluble tetrazolium/formazan assay for cell growth and drug sensitivity in culture using human and other tumor cell lines. Cancer Res 1988;48:4827-4833.
4. Floersheim GL: Uptake of vital H3-labeled deoxyribonucleic acid in spleen and bone marrow cells in vitro. Nucl.Med.(Stuttg) 1963;2:Suppl-9.
5. Zak J, Schneider SW, Eue I, Ludwig T, Oberleithner H: High-resistance MDCK-C7 monolayers used for measuring invasive potency of tumour cells. Pflugers Arch 2000;440:179-183.
6. Ludwig T, Ossig R, Graessel S, Wilhelmi M, Oberleithner H, Schneider SW: The electrical resistance breakdown assay determines the role of proteinases in tumor cell invasion. Am J Physiol Renal Physiol 2002;283:F319-F327.
7. Schneider SW, Ludwig T, Tatenhorst L, Braune S, Oberleithner H, Senner V, Paulus W: Glioblastoma cells release factors that disrupt bloodbrain barrier features. Acta Neuropathol.(Berl) 2004;107:272-276.
8. Ludwig T, Riethmuller C, Gekle M, Schwerdt G, Oberleithner H: Nephrotoxicity of Platinum Complexes is related to basolateral organic Cation Transport. Kidney Int 2004, in press.
9. Ludwig T, Oberleithner H: Platinum Complex Toxicity in cultured renal Epithelia. Cell Physiol Biochem 2004, in press.
10. Gekle M, Wunsch S, Oberleithner H, Silbernagl S: Characterization of two MDCK-cell subtypes as a model system to study principal cell and intercalated cell properties. Pflugers Arch 1994;428:157-162.
11. Wunsch S, Gekle M, Kersting U, Schuricht B, Oberleithner H: Phenotypically and karyotypically distinct Madin-Darby canine kidney cell clones respond differently to alkaline stress. J Cell Physiol 1995;164:164-171.
12. Kobayashi T, Hayashi A, Ura-Ishikou A, Tajima S, Nishikawa T: A novel gelatinolytic enzyme secreted by amelanotic cells isolated from B16 melanoma cell line. Cancer Lett 1994;85:165-169.
13. Oberleithner H, Westphale HJ, Gassner B: Alkaline stress transforms Madin-Darby canine kidney cells. Pflugers Arch 1991;419:418-420.
14. Browder T, Butterfield CE, Kraling BM, Shi B, Marshall B, O'Reilly MS, Folkman J: Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 2000;60:1878-1886.
15. Bocci G, Nicolaou KC, Kerbel RS: Protracted low-dose effects on human endothelial cell proliferation and survival in vitro reveal a selective antiangiogenic window for various chemotherapeutic drugs. Cancer Res 2002;62:6938-6943.
16. Leonard BJ, Eccleston E, Jones D, Todd P, Walpole A: Antileukaemic and nephrotoxic properties of platinum compounds. Nature 1971;234:43-45.
17. Hartmann JT, Lipp HP: Toxicity of platinum compounds. Expert.Opin Pharmacother 2003;4:889-901.
18. Rosenberg B, Vancamp l, Krigas T: Inhibition of cell division in escherichia coli by electrolysis products from a platinum electrode. Nature1965;205:698-699.
19. Rosenberg B, Vancamp l, Trosko JE, Mansour VH: Platinum compounds: a new class of potent antitumour agents. Nature 1969;222:385-386.
20. O'Dwyer PJ, Stevenson JP, Johnson SW: Clinical pharmacokinetics and administration of established platinum drugs. Drugs 59 Suppl 2000;4:19-27.
21. Boulikas T, Vougiouka M: Recent clinical trials using cisplatin, carboplatin and their combination chemotherapy drugs. Oncol Rep 2004;11:559-595.
22. Eigentler TK, Caroli UM, Radny P, Garbe C: Palliative therapy of disseminated malignant melanoma: a systematic review of 41 randomised clinical trials. Lancet Oncol 2003;4:748-759.
23. Alberts DS, Green S, Hannigan EV, O'Toole R, Stock-Novack D, Anderson P, Surwit EA, Malvlya VK, Nahhas WA, Jolles CJ: Improved therapeutic index of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide: final report by the Southwest Oncology Group of a phase III randomized trial in stages III and IV ovarian cancer. J Clin Oncol 1992;10:706-717.
24. Bajorin DF, Sarosdy MF, Pfister DG, Mazumdar M, Motzer RJ, Scher HI, Geller NL, Fair WR, Herr H, Sogani P: Randomized trial of etoposide and cisplatin versus etoposide and carboplatin in patients with good-risk germ cell tumors: a multiinstitutional study. J Clin Oncol 1993;11:598-606.
25. De Andres L, Brunet J, Lopez-Pousa A, Burgues J, Vega M, Tabernero JM, Mesia R, Lopez JJ: Randomized trial of neoadjuvant cisplatin and fluorouracil versus carboplatin and fluorouracil in patients with stage IV-M0 head and neck cancer. J Clin Oncol 1995;13:1493-1500.
26. Go RS, Adjei AA: Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin. J Clin Oncol 1999;17:409-422.
27. Mohammed MQ, Retsas S: Oxaliplatin is active in vitro against human melanoma cell lines: comparison with cisplatin and carboplatin. Anticancer Drugs 2000;11:859-863.
28. Li Y, McClay EF: Systemic chemotherapy for the treatment of metastatic melanoma. Semin Oncol 2002;29:413-426.